IL-2 Appears to Enhance Effects of Antiretroviral Therapy

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 8
Volume 9
Issue 8

BETHESDA, Md-The addition of interleukin-2 (IL-2) to standard anti-retroviral therapy significantly improved CD4 cell response in HIV-infected patients, reported Richard T. Davey Jr, MD, of the National Institute of Allergy and Infectious Diseases.

BETHESDA, Md—The addition of interleukin-2 (IL-2) to standard anti-retroviral therapy significantly improved CD4 cell response in HIV-infected patients, reported Richard T. Davey Jr, MD, of the National Institute of Allergy and Infectious Diseases.

This randomized, controlled multi-center trial, conducted from April 1996 through April 1998, included 78 adult outpatients with HIV and baseline CD4 cell counts of 200 to 500 × 106/L and baseline HIV-1 RNA levels of fewer than 10,000 copies/mL. Patients were randomized to receive subcutaneous IL-2, given in 5-day courses every 8 weeks at a starting dosage of 7.5 mIU twice daily plus antiretroviral therapy or antiretroviral therapy alone.

At 1 year, patients who received IL-2 had a mean percentage increase in CD4 cell counts of 112%, compared with 18% for the group receiving antiretroviral therapy alone (P < .001). CD4 cell percen-tages rose from a mean of 20% to 32% in the combination therapy group and from 20% to 23% in the group receiving antiretroviral therapy only (P < .001).

Of 30 evaluable patients receiving IL-2, 20 (67%) achieved a final viral load of fewer than 50 copies/mL, compared with 13 (36%) of 36 control patients (P = .02) (JAMA 284:183-189, 2000).

Toxic effects were common among patients who received IL-2, the researchers said, and were managed with anti-pyretics, hydration, rest, and dosage reduction as needed.

“Clinical endpoint trials will be necessary to determine whether the enhanced viral suppression and CD4 cell increases associated with IL-2 therapy will translate into improved clinical outcomes,” the researchers said.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Ongoing studies in kidney cancer aim to explore determinants of immune-related adverse effects and strategies for mitigating them.
Machine learning-based approaches may play a role in further understanding of how somatic alterations influence responses or resistance to therapy.